Leukemia, Myeloid, Acute: all 3,035 studies
Page 5 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCTRecruitingNCT06447090Phase 2
- A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After TransplantationNot yet recruitingNCT06441084Phase 1
- Ziftomenib Maintenance Post Allo-HCTRecruitingNCT06440135Phase 1
- Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive ChemotherapyRecruitingNCT06439199
- MB-dNPM1-TCR.1 in Relapsed/Refractory AMLRecruitingNCT06424340Phase 1/2
- Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AMLRecruitingNCT06420063Phase 1/2
- IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AMLRecruitingNCT06418776Phase 3
- Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaRecruitingNCT06399640Phase 1
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML PatientsRecruitingNCT06394011Phase 2
- A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaRecruitingNCT06389292Phase 3
- A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid LeukemiaNot yet recruitingNCT06387420Phase 1/2
- A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid LeukemiaRecruitingNCT06387069Phase 3
- Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT06386302Not applicable
- Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AMLNot yet recruitingNCT06385808Not applicable
- Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation TherapyRecruitingNCT06382922
- DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06382168Phase 1/2
- A Study of GLB-001 in Patients With Myeloid MalignanciesRecruitingNCT06378437Phase 1
- OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid LeukemiaRecruitingNCT06377579
- A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDSRecruitingNCT06372717Phase 1
- Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-InequalityRecruitingNCT06370000Phase 4
- Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT06357182Phase 1
- BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in ChildrenNot yet recruitingNCT06347458Phase 1
- MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingNCT06345365Phase 3
- Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)RecruitingNCT06345027Phase 1
- A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AMLRecruitingNCT06329999Not applicable
- Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.RecruitingNCT06328179Not applicable
- CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological MalignanciesRecruitingNCT06326463Phase 1
- Interest of Light Therapy in Hematology - The PHOTO-TREAT StudyRecruitingNCT06326268Not applicable
- Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid LeukaemiaRecruitingNCT06326021Phase 1
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)RecruitingNCT06317649Phase 2
- Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT MutationRecruitingNCT06316960Phase 2
- Revumenib in Combination With 7+3 + Midostaurin in AMLRecruitingNCT06313437Phase 1
- CLL-1 CAR-NK Cells for Relapsed/Refractory AMLRecruitingNCT06307054Phase 1
- MRD Response-adapted Allo-HSCT for Adverse-risk AMLRecruitingNCT06301425Not applicable
- Study of REM-422 in Patients With AML or Higher Risk MDSRecruitingNCT06297941Phase 1
- Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)RecruitingNCT06297551
- Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and GenomicsNot yet recruitingNCT06295029
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingNCT06287944Phase 1
- Phase I Study of HC-7366 for Acute Myeloid LeukemiaRecruitingNCT06285890Phase 1
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibRecruitingNCT06284486Phase 1/2
- An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid LeukaemiaNot yet recruitingNCT06281847Phase 1/2
- Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction ChemotherapyRecruitingNCT06279572
- Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia PatientsNot yet recruitingNCT06252584Phase 1
- UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid LeukemiaRecruitingNCT06245746Phase 1
- Study of IBR733 Cell Injection in Acute Myeloid LeukemiaRecruitingNCT06234904Phase 1
- Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity TestRecruitingNCT06233526Not applicable
- Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AMLRecruitingNCT06232694Not applicable
- Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid LeukemiaRecruitingNCT06225128
- SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 MutationRecruitingNCT06222580Phase 1
- VAC Regimen for AML Patients Who Failed to Response to VA RegimenRecruitingNCT06220162Phase 2
- Off-the-shelf CD123 CAR-NK for R/R AMLRecruitingNCT06201247Early Phase 1
- A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS PatientsRecruitingNCT06199557Phase 1/2
- A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)RecruitingNCT06191978Phase 1
- Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AMLRecruitingNCT06191263Phase 2
- D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid LeukemiaNot yet recruitingNCT06188182
- A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid LeukemiaNot yet recruitingNCT06182592Phase 3
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingNCT06177067Phase 1
- Role of BMP Pathway in MDS ProgressionNot yet recruitingNCT06175923
- Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML PatientsEnrolling by invitationNCT06162325
- Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AMLRecruitingNCT06158828Phase 1/2
- CIML NK Cells With Venetoclax for AMLRecruitingNCT06152809Phase 1
- A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic SyndromesRecruitingNCT06146257Phase 1
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingNCT06138587Phase 1
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801
- Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantRecruitingNCT06129734Phase 1/2
- Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeRecruitingNCT06128070Phase 2
- Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)RecruitingNCT06125652Phase 1/2
- Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06118788Phase 1/2
- Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AMLRecruitingNCT06105658Phase 2
- Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06084819Phase 2
- A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid LeukemiaRecruitingNCT06073769
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantRecruitingNCT06059391Phase 2
- Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDSNot yet recruitingNCT06050941Phase 2
- A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological MalignanciesRecruitingNCT06049667Phase 1
- Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSRecruitingNCT06046313Phase 2
- Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)RecruitingNCT06045819
- MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic StrategiesNot yet recruitingNCT06022341Not applicable
- Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.RecruitingNCT06022016Not applicable
- Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid LeukemiaRecruitingNCT06022003Phase 2
- A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid LeukemiaRecruitingNCT06017258Phase 1
- A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AMLRecruitingNCT06014489Phase 2
- Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesRecruitingNCT06013423Phase 2
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06001788Phase 1
- Universal CAR-T Cells Targeting AMLNot yet recruitingNCT05995041Phase 1
- Universal 4SCAR7U Targeting CD7-positive MalignanciesNot yet recruitingNCT05995028Phase 1
- Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid MalignanciesRecruitingNCT05991908Phase 3
- Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AMLRecruitingNCT05986240Phase 1
- Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline MutationRecruitingNCT05983991Not applicable
- Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid LeukemiaEnrolling by invitationNCT05983172
- Acute Myeloid Leukemia RegistryRecruitingNCT05979675
- Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom MonitoringRecruitingNCT05974150
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaRecruitingNCT05955261Phase 2
- Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)RecruitingNCT05949125Phase 1
- A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)RecruitingNCT05947344Phase 1
- CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AMLRecruitingNCT05945849Phase 1
- Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid LeukemiaNot yet recruitingNCT05944211Phase 2
- VA vs DA for Newly Diagnosed Hig-risk AMLRecruitingNCT05939180Phase 2/3
- A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05924750Phase 1
- PET Tracer Based FDG Signal for Predicting Prognosis in Acute Myeloid LeukemiaEnrolling by invitationNCT05919199